APPLIED DNA SCIENCES, INC. Applied DNA Sciences, Inc. Share Price
Equities
APDN
US03815U4094
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.37 USD | -12.60% |
|
-36.32% | -64.58% |
| Sales 2024 * | 5.02M 402M | Sales 2025 * | 8.17M 654M | Capitalization | 3.77M 302M |
|---|---|---|---|---|---|
| Net income 2024 * | -12M -961M | Net income 2025 * | -13M -1.04B | EV / Sales 2024 * | 0.75 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.46 x |
| P/E ratio 2024 * |
-0.34
x | P/E ratio 2025 * |
-0.41
x | Employees | 54 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.56% |
More Fundamentals
* Assessed data
More news
Latest transcript on Applied DNA Sciences, Inc.
More recommendations
More press releases
More news
| 1 day | -12.60% | ||
| 1 week | -36.32% | ||
| Current month | -46.71% | ||
| 1 month | -48.95% | ||
| 3 months | -64.87% | ||
| 6 months | -73.66% | ||
| Current year | -64.58% |
1 week
4.07
7.10
1 month
4.079.20
Current year
4.0714.40
1 year
4.0737.20
3 years
4.07162.00
5 years
4.07672.00
10 years
4.077 760.00
| Managers | Title | Age | Since |
|---|---|---|---|
James Hayward
CEO | Chief Executive Officer | 71 | 27/09/05 |
Beth Jantzen
DFI | Director of Finance/CFO | 47 | 30/04/13 |
Lawrence Jung
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yacov Shamash
BRD | Director/Board Member | 74 | 16/03/06 |
Bob Catell
BRD | Director/Board Member | 87 | 06/10/16 |
James Hayward
CEO | Chief Executive Officer | 71 | 27/09/05 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 4.37 | -12.60% | 84,077 |
| 25/04/24 | 5 | +4.69% | 102,239 |
| 24/04/24 | 4.776 | -17.66% | 61,058 |
| 23/04/24 | 5.8 | -12.12% | 42,394 |
| 22/04/24 | 6.6 | -3.82% | 1,791 |
Delayed Quote Nasdaq, April 26, 2024 at 09:30 pm
More quotes
Applied DNA Sciences, Inc. is a biotechnology company that develops, and markets deoxyribonucleic acid (DNA) based technology solutions. The Company is utilizing its LinearDNA large-scale polymerase chain reaction (PCR) based manufacturing platform. The Companyâs proprietary platform produces large quantities of DNA for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets and for supply chain security, anti-counterfeiting and anti-theft technology purposes. It also develops PCR-based molecular in vitro diagnostics for covid-19. In addition, under its wholly owned subsidiary, Applied DNA Clinical Labs, LLC, the Company is offering a high-throughput turnkey solution for population-scale Covid-19 testing marketed as safeCircle. safeCircle utilizes the Companyâs Covid-19 Diagnostic Tests and is designed to look for infection within defined populations or communities utilizing high throughput testing methodologies.
Calendar
08/05/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
4.37
USD
Average target price
45
USD
Spread / Average Target
+929.75%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -64.58% | 3.77M | |
| +0.89% | 12.8B | |
| -10.29% | 7.61B | |
| +1.78% | 5.41B | |
| -1.16% | 4.51B | |
| +5.74% | 4.49B | |
| -50.70% | 3.3B | |
| +12.21% | 2.73B | |
| -16.13% | 2.02B | |
| -11.50% | 1.73B |
- Stock Market
- Equities
- APDN Stock
